Efficacy and Safety of Xuesaitong Soft Capsule for Coronary Heart Disease Unstable Angina
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03083119|
Recruitment Status : Unknown
Verified March 2017 by Jie Wang, Guang'anmen Hospital of China Academy of Chinese Medical Sciences.
Recruitment status was: Recruiting
First Posted : March 17, 2017
Last Update Posted : March 17, 2017
|Condition or disease||Intervention/treatment||Phase|
|Coronary Heart Disease Unstable Angina||Drug: Xuesaitong soft capsule Drug: Placebo oral capsule||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||70 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Investigator, Outcomes Assessor)|
|Official Title:||The Methylation Regulation Mechanism of Blood Stasis Relevant miRNA Expression on Coronary Heart Disease|
|Estimated Study Start Date :||March 20, 2017|
|Estimated Primary Completion Date :||April 20, 2017|
|Estimated Study Completion Date :||August 20, 2017|
Experimental: Xuesaitong soft capsule group
Patients who confirmed by coronary angiography and diagnosed blood stasis syndrome of coronary heart disease are given conventional Western medicine treatment and Xuesaitong soft capsule.
Drug: Xuesaitong soft capsule
Panax Notoginseng Saponins, Specification:0.33 per bag, once take two pills and twice a day during a month.
Placebo Comparator: Placebo Comparator
Patients who confirmed by coronary angiography and diagnosed blood stasis syndrome of coronary heart disease are given conventional Western medicine treatment and placebo.
Drug: Placebo oral capsule
Xuesaitong soft capsule Placebo, soft capsule, once take two pills and twice a day during a month.
- major adverse cardiovascular events [ Time Frame: 60 days ]death, myocardial infarction, hospitalization for unstable angina or stroke
- Seattle Angina Questionnaire [ Time Frame: 60 days ]to evaluate patients by Seattle Angina Questionnaire
- blood stasis syndrome scale of Coronary heart disease angina pectoris [ Time Frame: 60 ]to evaluate patients by blood stasis syndrome scale of Coronary heart disease angina pectoris
- lipid [ Time Frame: 60 ]Triacylglyceride,total cholesterol, low densith lipoprotein, high densith lipoprotein
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03083119
|Contact: Lian Duanemail@example.com|
|Guang Anmen Hospital||Recruiting|
|Beijing, Beijing, China, 100029|
|Contact: Lian Duan +8601088001817 firstname.lastname@example.org|
|Principal Investigator:||Jie Wang||Guang Anmen Hospital|